Ambroxol
Therapeutic Indications
Ambroxol is indicated for:
Mucolytic therapy
Irrespective of gender only Children (1 year - 12 years old)
Ambroxol is indicated for mucolytic therapy of productive cough associated with acute or chronic bronchopulmonary diseases.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 7.5-15 mg 3 3 times daily
Treatment 2: Intravenous - 30 mg/kg body weight per day, divided into four single doses
Mucolytic therapy
Irrespective of gender only Adolescents (12 years - 18 years old) , Adults (18 - 65 years old)
Ambroxol is indicated for mucolytic therapy of productive cough associated with acute or chronic bronchopulmonary diseases.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 30 mg/kg body weight per day, divided into four single doses
Treatment 2: Oral - 30 mg 3 times daily
Contraindications
Active ingredient Ambroxol is contraindicated in the following cases:
Antitussives or with drugs that have an atropic effect
No gender/age discrimination
Ambroxol should not be given concomitantly with antitussives or with drugs that have an atropic effect.
Breast-feeding
No gender/age discrimination
Ambroxol crosses into the breast milk in animals. As there is no adequate experience in humans to date, ambroxol should only be used in lactation after careful benefit/risk assessment.
Pregnancy
No gender/age discrimination
There are no sufficient data for the use of ambroxol in pregnant women. This particularly concerns the period up to the 28th week of pregnancy. Ambroxol has shown no teratogenic effects in animal-experiment studies. Ambroxol should only be used in pregnancy after careful benefit/risk evaluation, particularly during the first trimester.